{"id":56885,"date":"2025-12-18T20:30:32","date_gmt":"2025-12-18T15:00:32","guid":{"rendered":"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/"},"modified":"2025-12-18T20:30:32","modified_gmt":"2025-12-18T15:00:32","slug":"edison-issues-report-on-mindmaze-therapeutics-mmtx","status":"publish","type":"post","link":"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/","title":{"rendered":"Edison Issues Report on MindMaze Therapeutics (MMTX)"},"content":{"rendered":"

<\/p>\n

London, United Kingdom–(Newsfile Corp. – December 18, 2025) – Edison issues report on MindMaze Therapeutics (SIX: MMTX).<\/p>\n

MindMaze Therapeutics is a commercial-stage health technology company pioneering AI-driven digital neurotherapeutic solutions for treatment and recovery after neurological events such as stroke and traumatic brain injury (TBI). Its unique, integrated and coordinated platform spans the full continuum of care. With the US FDA and CE\/MDR registrations and a unique US CPT Category III (CAT III) reimbursement for home-based therapy, MindMaze is primed for commercial rollout across the US and Europe.<\/p>\n

Click here<\/b><\/a> to read the full report.<\/p>\n

All reports published by Edison are available to download free of charge from its website\u00a0www.edisongroup.com<\/b><\/a>.<\/p>\n

Edison is authorised and regulated by the Financial Conduct Authority<\/b><\/a>.<\/p>\n

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.<\/p>\n

\n

For more information, please contact Edison:<\/b><\/p>\n

enquiries@edisongroup.com<\/b><\/a>
+44 (0)20 3077 5700<\/p>\n<\/div>\n

Connect with Edison on:<\/p>\n

LinkedIn www.linkedin.com\/company\/edison-group-\/<\/b><\/a>
X www.x.com\/edison_inv_res<\/b><\/a>
YouTube www.youtube.com\/edisonitv<\/b><\/a><\/p>\n

\"Corporate<\/p>\n

To view the source version of this press release, please visit https:\/\/www.newsfilecorp.com\/release\/278512<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

London, United Kingdom–(Newsfile Corp. – December 18, 2025) – Edison issues report on MindMaze Therapeutics (SIX: MMTX). MindMaze Therapeutics is a commercial-stage health technology company pioneering AI-driven digital neurotherapeutic solutions for treatment and recovery after neurological events such as stroke and traumatic brain injury (TBI). Its unique, integrated and coordinated platform spans the full continuum …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[130],"tags":[],"class_list":["post-56885","post","type-post","status-publish","format-standard","","category-international"],"yoast_head":"\nEdison Issues Report on MindMaze Therapeutics (MMTX) - Matribhumi Samachar English<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Edison Issues Report on MindMaze Therapeutics (MMTX) - Matribhumi Samachar English\" \/>\n<meta property=\"og:description\" content=\"London, United Kingdom–(Newsfile Corp. – December 18, 2025) – Edison issues report on MindMaze Therapeutics (SIX: MMTX). MindMaze Therapeutics is a commercial-stage health technology company pioneering AI-driven digital neurotherapeutic solutions for treatment and recovery after neurological events such as stroke and traumatic brain injury (TBI). Its unique, integrated and coordinated platform spans the full continuum …\" \/>\n<meta property=\"og:url\" content=\"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/\" \/>\n<meta property=\"og:site_name\" content=\"Matribhumi Samachar English\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-18T15:00:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/api.newsfilecorp.com\/newsinfo\/278512\/511\" \/>\n<meta name=\"author\" content=\"Saransh Kanaujia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Saransh Kanaujia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/\",\"url\":\"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/\",\"name\":\"Edison Issues Report on MindMaze Therapeutics (MMTX) - Matribhumi Samachar English\",\"isPartOf\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#website\"},\"datePublished\":\"2025-12-18T15:00:32+00:00\",\"dateModified\":\"2025-12-18T15:00:32+00:00\",\"author\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1\"},\"breadcrumb\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/matribhumisamachar.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Edison Issues Report on MindMaze Therapeutics (MMTX)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#website\",\"url\":\"https:\/\/matribhumisamachar.com\/en\/\",\"name\":\"Matribhumi Samachar English\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/matribhumisamachar.com\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1\",\"name\":\"Saransh Kanaujia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g\",\"caption\":\"Saransh Kanaujia\"},\"description\":\"Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.\",\"sameAs\":[\"https:\/\/matribhumisamachar.com\/en\"],\"url\":\"https:\/\/matribhumisamachar.com\/en\/author\/matribhumisamachar\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Edison Issues Report on MindMaze Therapeutics (MMTX) - Matribhumi Samachar English","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/","og_locale":"en_US","og_type":"article","og_title":"Edison Issues Report on MindMaze Therapeutics (MMTX) - Matribhumi Samachar English","og_description":"London, United Kingdom–(Newsfile Corp. – December 18, 2025) – Edison issues report on MindMaze Therapeutics (SIX: MMTX). MindMaze Therapeutics is a commercial-stage health technology company pioneering AI-driven digital neurotherapeutic solutions for treatment and recovery after neurological events such as stroke and traumatic brain injury (TBI). Its unique, integrated and coordinated platform spans the full continuum …","og_url":"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/","og_site_name":"Matribhumi Samachar English","article_published_time":"2025-12-18T15:00:32+00:00","og_image":[{"url":"https:\/\/api.newsfilecorp.com\/newsinfo\/278512\/511"}],"author":"Saransh Kanaujia","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Saransh Kanaujia","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/","url":"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/","name":"Edison Issues Report on MindMaze Therapeutics (MMTX) - Matribhumi Samachar English","isPartOf":{"@id":"https:\/\/matribhumisamachar.com\/en\/#website"},"datePublished":"2025-12-18T15:00:32+00:00","dateModified":"2025-12-18T15:00:32+00:00","author":{"@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1"},"breadcrumb":{"@id":"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/matribhumisamachar.com\/en\/2025\/12\/18\/edison-issues-report-on-mindmaze-therapeutics-mmtx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/matribhumisamachar.com\/en\/"},{"@type":"ListItem","position":2,"name":"Edison Issues Report on MindMaze Therapeutics (MMTX)"}]},{"@type":"WebSite","@id":"https:\/\/matribhumisamachar.com\/en\/#website","url":"https:\/\/matribhumisamachar.com\/en\/","name":"Matribhumi Samachar English","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/matribhumisamachar.com\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1","name":"Saransh Kanaujia","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g","caption":"Saransh Kanaujia"},"description":"Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.","sameAs":["https:\/\/matribhumisamachar.com\/en"],"url":"https:\/\/matribhumisamachar.com\/en\/author\/matribhumisamachar\/"}]}},"_links":{"self":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/56885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/comments?post=56885"}],"version-history":[{"count":0,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/56885\/revisions"}],"wp:attachment":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media?parent=56885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/categories?post=56885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/tags?post=56885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}